Selected article for: "treatment diagnosis and Trial version"

Author: Furong Liu; Xin Long; Wenbin Zou; Minghao Fang; Wenjuan Wu; Wei Li; Bixiang Zhang; Wanguang Zhang; Xiaoping Chen; Zhanguo Zhang
Title: Highly ACE2 Expression in Pancreas May Cause Pancreas Damage After SARS-CoV-2 Infection
  • Document date: 2020_3_3
  • ID: 6uaj8fb7_9
    Snippet: This is a retrospective and observational study from Wuhan Tongji hospital and Wuhan Jin Yin-tan hospital. We retrospectively analyzed patients diagnosed with COVID-19 from January 1, 2020 to February 15, 2020. The criteria for the diagnosis and severity of the patients were followed by the diagnosis and treatment scheme for COVID-19 (trial version 6) issued by National Health Commission of the People's Republic of China. We collect hospital admi.....
    Document: This is a retrospective and observational study from Wuhan Tongji hospital and Wuhan Jin Yin-tan hospital. We retrospectively analyzed patients diagnosed with COVID-19 from January 1, 2020 to February 15, 2020. The criteria for the diagnosis and severity of the patients were followed by the diagnosis and treatment scheme for COVID-19 (trial version 6) issued by National Health Commission of the People's Republic of China. We collect hospital admissions, laboratory tests, and imaging tests from clinical electronic medical records. In this study, we collected clinical information including age, gender, amylase and lipase in serum, and the imaging results including bedside ultrasound and abdominal CT. Mild COVID-19 patients with serum amylase and lipase in the normal range did not undergo the imaging evaluation of the pancreas, and their pancreas was assumed to be normal. Bedside ultrasound of the abdomen was all performed in critically ill patients, and CT was added if there were any abnormalities.

    Search related documents:
    Co phrase search for related documents